Schubert & Co’s BeOne Medicines Ltd ONC Stock Holding History

Schubert & Co’s Portfolio ONC Stock Details ONC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-2	Closed	-$432	–	1585
2023 Q1	$432	Hold	2	–	–	﹤0.01%	1448
2022 Q4	$440	Buy	+2	New	+$367	﹤0.01%	1418

Other funds holding ONC

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

CII

Capital International Inc Los Angeles, California $14.3B AUM 34.19% 1-Year Est. Return

Schubert & Co's ONC Position: Q2 2023 in Review

Schubert & Co sold out of BeOne Medicines Ltd (ONC) in Q2 2023, closing a stake of 2 shares — an estimated $432 sold.

Schubert & Co first reported a position in ONC in Q4 2022 and held it in 2 quarters. The position peaked at $440 in Q4 2022. 208 funds tracked by Wall St. Rank hold ONC as of Q2 2023.

Schubert & Co reported no remaining BeOne Medicines Ltd position as of Q2 2023 after selling out during the quarter.
Schubert & Co sold 2 BeOne Medicines Ltd shares in Q2 2023, an estimated $432.
Schubert & Co first reported a position in BeOne Medicines Ltd in Q4 2022 and held it in 2 quarters.
Schubert & Co's BeOne Medicines Ltd position peaked at $440 in Q4 2022.
208 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q2 2023.

Based on Schubert & Co's 13F filing for Q2 2023, filed 4 Aug 2023.